Background The risk of severe COVID-19 outcomes in people with immune-mediated
inflammatory diseases and on immune-modifying drugs might not be fully mediated by …

At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory
diseases were considered to be at high risk for SARS-CoV-2 infection and the development …

Objective To investigate coronavirus disease 2019 (COVID-19) hospitalization risk in
patients with immune-mediated inflammatory diseases (IMIDs) compared with matched non …

Background Many individuals take long-term immunosuppressive medications. We
evaluated whether these individuals have worse outcomes when hospitalised with COVID …

Background Real-world evidence on the association between autoimmune inflammatory
rheumatic diseases, therapies related to these diseases, and COVID-19 outcomes are …

Objective Patients with systemic autoimmune rheumatic diseases (ARDs) continue to be
concerned about risks of severe coronavirus disease 2019 (COVID‐19) outcomes. This …

Objective Patients with autoimmune diseases were advised to shield to avoid coronavirus
disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized …

Current data suggest that similar to the general population, age, and comorbidities are risk
factors for poorer COVID-19 outcomes in patients with IMID. Additional research is needed …

Background Some patients with systemic autoimmune rheumatic disease and
immunosuppression might still be at risk of severe COVID-19. The effect of outpatient SARS …

Objectives The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly
known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with …